Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
Microbot Medical (MBOT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Microbot Medical (MBOT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System